Efficacy and safety of privigen in children and adolescents with primary immunodeficiency

Joseph A. Church, Michael Borte, Hassan Taki, Robert Nelson, John W. Sleasman, Alan P. Knutsen, Edouard Le Gall, Marianne Debre, Peter Kiessling

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen ®, the first 10% liquid intravenous immunoglobulin stabilized with L-proline, in patients with primary immunodeficiency. As part of a larger study, 19 children (3-11 years) and 12 adolescents (12-15 years) received Privigen 200-741 mg/kg intravenously for 12 months at a maximum infusion rate of 8 mg/kg/min. Thirteen patients received infusions at up to 12 mg/kg/min as part of an extension study. The primary endpoint was the annual rate of acute serious bacterial infections (aSBIs) per patient. Privigen was effective, as indicated by the annual rate of aSBI of 0.12 per patient (upper 1-sided 99% CI 0.499) in 3- to 11-year-olds and 0.10 (CI 0.642) in 12- to 15-year-olds. Three patients experienced 1 aSBI each, but did not discontinue treatment. The annual rate of all infections (including aSBIs) per patient was 4.63 in children and 2.42 in adolescents. The annual rate of days missed from school/day care was 11.5 days in children and 4.8 days in adolescents, consistent with the low annual rate of hospitalization (0.53 days and 0 days, respectively). Privigen administration was well-tolerated even at high infusion rates. The proportion of infusions with temporally associated AEs for the entire pediatric population was 0.18 (upper 1-sided 95% CI 0.221). One patient experienced serious AEs considered related to study drug and was withdrawn. Privigen was effective in sustaining a low incidence of infections, including aSBIs, and showed a good tolerability profile, with adverse events typical of disease and treatment.

Original languageEnglish (US)
Pages (from-to)53-61
Number of pages9
JournalPediatric Asthma, Allergy and Immunology
Volume22
Issue number2
DOIs
StatePublished - Jun 1 2009

Fingerprint

Intravenous Immunoglobulins
Bacterial Infections
Safety
Infection
Proline
Hospitalization
Pediatrics
Incidence
Therapeutics
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Efficacy and safety of privigen in children and adolescents with primary immunodeficiency. / Church, Joseph A.; Borte, Michael; Taki, Hassan; Nelson, Robert; Sleasman, John W.; Knutsen, Alan P.; Le Gall, Edouard; Debre, Marianne; Kiessling, Peter.

In: Pediatric Asthma, Allergy and Immunology, Vol. 22, No. 2, 01.06.2009, p. 53-61.

Research output: Contribution to journalArticle

Church, JA, Borte, M, Taki, H, Nelson, R, Sleasman, JW, Knutsen, AP, Le Gall, E, Debre, M & Kiessling, P 2009, 'Efficacy and safety of privigen in children and adolescents with primary immunodeficiency', Pediatric Asthma, Allergy and Immunology, vol. 22, no. 2, pp. 53-61. https://doi.org/10.1089/pai.2009.0005
Church, Joseph A. ; Borte, Michael ; Taki, Hassan ; Nelson, Robert ; Sleasman, John W. ; Knutsen, Alan P. ; Le Gall, Edouard ; Debre, Marianne ; Kiessling, Peter. / Efficacy and safety of privigen in children and adolescents with primary immunodeficiency. In: Pediatric Asthma, Allergy and Immunology. 2009 ; Vol. 22, No. 2. pp. 53-61.
@article{92f59acfcec548b8bc694f6cc7d8857f,
title = "Efficacy and safety of privigen in children and adolescents with primary immunodeficiency",
abstract = "The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen {\circledR}, the first 10{\%} liquid intravenous immunoglobulin stabilized with L-proline, in patients with primary immunodeficiency. As part of a larger study, 19 children (3-11 years) and 12 adolescents (12-15 years) received Privigen 200-741 mg/kg intravenously for 12 months at a maximum infusion rate of 8 mg/kg/min. Thirteen patients received infusions at up to 12 mg/kg/min as part of an extension study. The primary endpoint was the annual rate of acute serious bacterial infections (aSBIs) per patient. Privigen was effective, as indicated by the annual rate of aSBI of 0.12 per patient (upper 1-sided 99{\%} CI 0.499) in 3- to 11-year-olds and 0.10 (CI 0.642) in 12- to 15-year-olds. Three patients experienced 1 aSBI each, but did not discontinue treatment. The annual rate of all infections (including aSBIs) per patient was 4.63 in children and 2.42 in adolescents. The annual rate of days missed from school/day care was 11.5 days in children and 4.8 days in adolescents, consistent with the low annual rate of hospitalization (0.53 days and 0 days, respectively). Privigen administration was well-tolerated even at high infusion rates. The proportion of infusions with temporally associated AEs for the entire pediatric population was 0.18 (upper 1-sided 95{\%} CI 0.221). One patient experienced serious AEs considered related to study drug and was withdrawn. Privigen was effective in sustaining a low incidence of infections, including aSBIs, and showed a good tolerability profile, with adverse events typical of disease and treatment.",
author = "Church, {Joseph A.} and Michael Borte and Hassan Taki and Robert Nelson and Sleasman, {John W.} and Knutsen, {Alan P.} and {Le Gall}, Edouard and Marianne Debre and Peter Kiessling",
year = "2009",
month = "6",
day = "1",
doi = "10.1089/pai.2009.0005",
language = "English (US)",
volume = "22",
pages = "53--61",
journal = "Pediatric, Allergy, Immunology, and Pulmonology",
issn = "2151-321X",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of privigen in children and adolescents with primary immunodeficiency

AU - Church, Joseph A.

AU - Borte, Michael

AU - Taki, Hassan

AU - Nelson, Robert

AU - Sleasman, John W.

AU - Knutsen, Alan P.

AU - Le Gall, Edouard

AU - Debre, Marianne

AU - Kiessling, Peter

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen ®, the first 10% liquid intravenous immunoglobulin stabilized with L-proline, in patients with primary immunodeficiency. As part of a larger study, 19 children (3-11 years) and 12 adolescents (12-15 years) received Privigen 200-741 mg/kg intravenously for 12 months at a maximum infusion rate of 8 mg/kg/min. Thirteen patients received infusions at up to 12 mg/kg/min as part of an extension study. The primary endpoint was the annual rate of acute serious bacterial infections (aSBIs) per patient. Privigen was effective, as indicated by the annual rate of aSBI of 0.12 per patient (upper 1-sided 99% CI 0.499) in 3- to 11-year-olds and 0.10 (CI 0.642) in 12- to 15-year-olds. Three patients experienced 1 aSBI each, but did not discontinue treatment. The annual rate of all infections (including aSBIs) per patient was 4.63 in children and 2.42 in adolescents. The annual rate of days missed from school/day care was 11.5 days in children and 4.8 days in adolescents, consistent with the low annual rate of hospitalization (0.53 days and 0 days, respectively). Privigen administration was well-tolerated even at high infusion rates. The proportion of infusions with temporally associated AEs for the entire pediatric population was 0.18 (upper 1-sided 95% CI 0.221). One patient experienced serious AEs considered related to study drug and was withdrawn. Privigen was effective in sustaining a low incidence of infections, including aSBIs, and showed a good tolerability profile, with adverse events typical of disease and treatment.

AB - The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen ®, the first 10% liquid intravenous immunoglobulin stabilized with L-proline, in patients with primary immunodeficiency. As part of a larger study, 19 children (3-11 years) and 12 adolescents (12-15 years) received Privigen 200-741 mg/kg intravenously for 12 months at a maximum infusion rate of 8 mg/kg/min. Thirteen patients received infusions at up to 12 mg/kg/min as part of an extension study. The primary endpoint was the annual rate of acute serious bacterial infections (aSBIs) per patient. Privigen was effective, as indicated by the annual rate of aSBI of 0.12 per patient (upper 1-sided 99% CI 0.499) in 3- to 11-year-olds and 0.10 (CI 0.642) in 12- to 15-year-olds. Three patients experienced 1 aSBI each, but did not discontinue treatment. The annual rate of all infections (including aSBIs) per patient was 4.63 in children and 2.42 in adolescents. The annual rate of days missed from school/day care was 11.5 days in children and 4.8 days in adolescents, consistent with the low annual rate of hospitalization (0.53 days and 0 days, respectively). Privigen administration was well-tolerated even at high infusion rates. The proportion of infusions with temporally associated AEs for the entire pediatric population was 0.18 (upper 1-sided 95% CI 0.221). One patient experienced serious AEs considered related to study drug and was withdrawn. Privigen was effective in sustaining a low incidence of infections, including aSBIs, and showed a good tolerability profile, with adverse events typical of disease and treatment.

UR - http://www.scopus.com/inward/record.url?scp=68949119374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949119374&partnerID=8YFLogxK

U2 - 10.1089/pai.2009.0005

DO - 10.1089/pai.2009.0005

M3 - Article

AN - SCOPUS:68949119374

VL - 22

SP - 53

EP - 61

JO - Pediatric, Allergy, Immunology, and Pulmonology

JF - Pediatric, Allergy, Immunology, and Pulmonology

SN - 2151-321X

IS - 2

ER -